Heron Therapeutics (HRTX) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings or view top-rated stocks.

2 brokerages have issued 1 year price targets for Heron Therapeutics' stock. Their HRTX share price forecasts range from $5.50 to $10.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 504.8% from the stock's current price.
View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts.

Heron Therapeutics' stock was trading at $2.50 at the beginning of 2023. Since then, HRTX stock has decreased by 50.4% and is now trading at $1.24.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our HRTX earnings forecast.

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to analysts' expectations of $27.24 million. Heron Therapeutics had a negative net margin of 132.57% and a negative trailing twelve-month return on equity of 21,127.62%. The company's revenue was up 44.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.54) earnings per share.

ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Simplify Propel Opportunities ETF (SURI).Invesco Nasdaq Future Gen 200 ETF (QQQS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Heron Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.88%), JPMorgan Chase & Co. (5.92%), Great Point Partners LLC (4.88%), Palisade Capital Management LP (3.33%), ArrowMark Colorado Holdings LLC (2.80%) and State Street Corp (2.14%). Insiders that own company stock include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard and Waage Christian.
View institutional ownership trends.

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HRTX stock can currently be purchased for approximately $1.24.

Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $148.44 million and generates $107.67 million in revenue each year. The biotechnology company earns $-182,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

The company employs 302 workers across the globe.

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490.